Gregg A. Lapointe
Gregg Lapointe is former CEO, Sigma-Tau Pharmaceuticals. His background includes extensive experience in the areas of biopharmaceutical global strategic planning and implementation, business development, corporate finance and acquisitions.
Gregg served in varying roles for Sigma-Tau Pharmaceuticals, Inc., a private biopharmaceutical company, starting in 2001, including Vice-President, Finance from 2001 to 2002, Chief Operating Officer from 2003 to 2007 and Chief Executive Officer from 2008 to 2012. He led the transformation of Sigma-Tau Pharmaceuticals from a small, specialty dialysis company into a global leader in the field of Rare Disease medicines, with a diversified product portfolio and extensive clinical pipeline.
Gregg serves on the Board of Directors of SciClone Pharmaceuticals, Inc., Soligenix, Inc. and is a member of the Corporate Council of the National Organization for Rare Disorders (NORD). He previously served on the Boards of Questcor Pharmaceuticals, Inc., and the Pharmaceutical Research and Manufacturers of America (PhRMA). From 1996 to 2001, he served as Vice President of Operations and Vice President, Controller of AstenJohnson, Inc. (formerly JWI Inc.). Prior to that, Gregg spent several years in the Canadian medical products industry in both distribution and manufacturing. Gregg began his career at Price Waterhouse.
Gregg received his B.A. degree in Commerce from Concordia University in Montreal, Canada, a graduate diploma in Accountancy from McGill University and his MBA from the Fuqua School of Business at Duke University. He is a Certified Public Accountant in the state of Illinois and a Chartered Accountant in Ontario, Canada.